Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study of TIL in Advanced Solid Tumors (CZ)
Sponsor: Shanghai Juncell Therapeutics
Summary
This study is to investigate the safety and efficacy of tumor infiltrating lymphocyte (TIL) therapy in patients with advanced solid tumors. Autologous TILs and gene-edited TILs are expanded from tumor resections and infused i.v. into the patient after NMA lymphodepletion treatment with hydroxychloroquine(600mg,single-dose) and cyclophosphamide.
Official title: A Study Study of Tumor Infiltrating Lymphocytes Injection (GC101/203 TIL) in Patients With Advanced Solid Tumors
Key Details
Gender
All
Age Range
18 Years - 70 Years
Study Type
INTERVENTIONAL
Enrollment
30
Start Date
2026-05-08
Completion Date
2029-09-20
Last Updated
2026-01-16
Healthy Volunteers
No
Conditions
Interventions
GC101TIL
A tumor sample is resected from each participant and cultured ex vivo to expand the population of Autologous Tumor Infiltrating Lymphocytes Injection (GC101 TIL). After lymphodepletion, patients are infused GC101 TIL.
Locations (1)
Sichuan Cancer Hospital & Institute, Sichuan Cancer Center
Chengdu, China